Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Yuhan Corporation

http://eng.yuhan.co.kr/Main/

Latest From Yuhan Corporation

Korean Biopharmas Rush To Boston: What Are The Challenges And Opportunities?

The head of the US arm of a major Korean government development institute talks to Scrip about why biotechs and pharma firms are flocking to Boston, how the organization is providing support and what the main challenges are.

South Korea Business Strategies

Trial Hot Spot: Australia's Attractions To The Korean Industry

Ausbiotech's CEO and the Australian government’s Senior Trade and Investment Commissioner in South Korea talk to Scrip on the sidelines of the Bio Korea 2022 meeting about what makes Australia an attractive clinical trial destination for Korean and other foreign pharma firms, as well as about collaborations and other opportunities between the two countries.

Australia Clinical Trials

Korea Q1 Roundup: Overseas Sales, COVID Prove Positive In Mixed Results

Among recent highlights, SK Bioscience files for approval of recombinant protein COVID-19 vaccine GBP510, Hanmi Pharmaceutical’s Chinese subsidiary continues to report strong earnings, led by cold drug sales, while Yuhan’s novel peptide drug candidate for degenerative disc disease is set to move into a Phase III trial in the US.

South Korea Sales & Earnings

Too Crowded? ImmuneOncia Looks To Niches To Challenge PD-L1 Space

ImmuneOncia CEO talks to Scrip about the development strategy for its anti-PD-L1 and anti-CD47 pipeline assets as well as the advantages of having Yuhan and Sorrento as its largest shareholders.

South Korea ImmunoOncology
See All

Company Information

  • Industry
  • Distributors
  • Pharmaceuticals
  • Pharmaceuticals
    • Generic Drugs
  • Biotechnology
    • Drug Discovery Tools
  • Other Names / Subsidiaries
    • Yuhan USA
UsernamePublicRestriction

Register